WO2011057254A3 - Simian adenoviral vector-based vaccines - Google Patents

Simian adenoviral vector-based vaccines Download PDF

Info

Publication number
WO2011057254A3
WO2011057254A3 PCT/US2010/056004 US2010056004W WO2011057254A3 WO 2011057254 A3 WO2011057254 A3 WO 2011057254A3 US 2010056004 W US2010056004 W US 2010056004W WO 2011057254 A3 WO2011057254 A3 WO 2011057254A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviral vector
simian adenoviral
antigen
based vaccines
pathogen
Prior art date
Application number
PCT/US2010/056004
Other languages
French (fr)
Other versions
WO2011057254A2 (en
Inventor
Gary J. Nabel
Cheng Cheng
Sung-Youl Ko
Jason G.D. Gall
Wing-Pui Kong
Douglas E. Brough
Duncan L. Mcvey
Christoph Kahl
Chih-Jen Wei
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Genvec, Inc. filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2011057254A2 publication Critical patent/WO2011057254A2/en
Publication of WO2011057254A3 publication Critical patent/WO2011057254A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a replication-deficient simian adenoviral vector construct comprising a nucleic acid sequence which encodes an antigen of a pathogen, such as an HIV antigen or an influenza virus antigen. The invention also provides a method of inducing an immune response against a pathogen, such as HIV or influenza, in a mammal using a composition comprising the simian adenoviral vector construct. The invention also provides a monkey adenovirus which is capable of propagation in a human cell.
PCT/US2010/056004 2009-11-09 2010-11-09 Simian adenoviral vector-based vaccines WO2011057254A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25934309P 2009-11-09 2009-11-09
US61/259,343 2009-11-09
US26231209P 2009-11-18 2009-11-18
US61/262,312 2009-11-18
US38699410P 2010-09-27 2010-09-27
US61/386,994 2010-09-27

Publications (2)

Publication Number Publication Date
WO2011057254A2 WO2011057254A2 (en) 2011-05-12
WO2011057254A3 true WO2011057254A3 (en) 2011-08-18

Family

ID=43568025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/056004 WO2011057254A2 (en) 2009-11-09 2010-11-09 Simian adenoviral vector-based vaccines

Country Status (1)

Country Link
WO (1) WO2011057254A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
EP2764011B1 (en) 2011-10-05 2021-04-07 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
EP2809346A1 (en) 2012-02-02 2014-12-10 GenVec, Inc. Adenoviral vector-based malaria vaccine
CN105051198A (en) * 2012-11-16 2015-11-11 貝丝以色列女执事医疗中心 Recombinant adenoviruses and use thereof
US9222142B2 (en) 2013-01-15 2015-12-29 The Regents Of The University Of California Adenoviruses and their use
US11773142B2 (en) 2017-12-11 2023-10-03 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
EP3856238A1 (en) * 2018-09-25 2021-08-04 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
CN113151193B (en) * 2021-03-23 2023-08-01 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Serum 4 type avian adenovirus reverse genetic vaccine strain rR188I, construction method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000283A1 (en) * 2001-06-22 2003-01-03 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
WO2003046124A2 (en) * 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2005071093A2 (en) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
WO2009073104A2 (en) * 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5130248A (en) 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAg
US5130247A (en) 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
HU216871B (en) 1993-07-13 1999-09-28 Rhone-Poulenc Rorer S.A. Defective adenovirus vectors and use thereof in gene therapy
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5962311A (en) 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
SI0833934T2 (en) 1995-06-15 2013-04-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
IL124654A0 (en) 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
WO1997020575A1 (en) 1995-12-08 1997-06-12 The University Of Alabama At Birmingham Research Foundation Targeted adenovirus vectors
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
BR9809173A (en) 1997-05-28 2000-08-01 Genvec Inc Alternatively targeted adenoviruses
US5944106A (en) 1997-08-06 1999-08-31 Halliburton Energy Services, Inc. Well treating fluids and methods
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
BR0010322A (en) 1999-05-06 2002-04-09 Univ Wake Forest Expression vector, vaccine and its method of use to elicit an immune response directed against an antigen in a mammal
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
FR2814642B1 (en) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En TRANSGENIC MOUSE FOR THE TARGETED RECOMBINATION MEDIATED BY THE MODIFIED CRE-ER
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
AU2002327380A1 (en) 2001-07-23 2003-03-18 Genvec, Inc. Cells and methods for propagating adenoviral vectors
WO2003022311A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
ES2478625T3 (en) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Method of generating chimeric adenoviruses and uses of such chimeric adenoviruses
WO2005034992A2 (en) 2003-09-15 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv vaccines based on env of multiple clades of hif
AU2006283101B2 (en) 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
EP1940867A2 (en) 2005-09-06 2008-07-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Hiv gp120 crystal structure and its use to identify immunogens
WO2010042817A1 (en) 2008-10-10 2010-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of hiv mosaic envelope proteins to optimize t-cell responses against hiv envelope

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000283A1 (en) * 2001-06-22 2003-01-03 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
WO2003046124A2 (en) * 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2005071093A2 (en) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
WO2009073104A2 (en) * 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DE SOUZA ET AL: "Genital CD8<+> T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 1, 8 December 2006 (2006-12-08), pages 109 - 116, XP005797690, ISSN: 0264-410X *
FARINA S F ET AL: "Replication-defective vector based on a Chimpanzee adenovirus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 23, 1 December 2001 (2001-12-01), pages 11603 - 11613, XP002957497, ISSN: 0022-538X, DOI: DOI:10.1128/JVI.75.23.11603-11613.2001 *
SRIDHAR S ET AL: "Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A", JOURNAL OF VIROLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 8, 1 April 2008 (2008-04-01), pages 3822 - 3833, XP009103960, ISSN: 1098-5514, DOI: DOI:10.1128/JVI.02568-07 *
TATSIS N ET AL: "Chimpanzee-origin adenovirus vectors as vaccine carriers", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 13, no. 5, 1 March 2006 (2006-03-01), pages 421 - 429, XP002527576, ISSN: 0969-7128, DOI: DOI:10.1038/SJ.GT.3302675 *

Also Published As

Publication number Publication date
WO2011057254A2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
NO20090194L (en) Recombinant viral vaccine
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2012177924A3 (en) Influenza virus mutants and uses therefor
EA201001491A1 (en) REPLICATION-DEFECT VACCINES AND VACCINE VECTORS AGAINST FLAVIVIRUSS
WO2010019262A3 (en) Polyvalent vaccine
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EA201171128A1 (en) OPTIMIZED EARLY / LATE PROMOTOR IN COMBINATION WITH REPEATED VACCINATION ASSISTED TO RESPONSE TO CYTOTOXIC T-CELLS AGAINST ANTIGENS OF RECOMBINANT VACCINES BASED ON VIRUS DEFICIENCY DEFICIENCY RESPECTIVE TO RECOMBINANT VACCINES.
WO2013164754A3 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
WO2007024941A3 (en) Polyvalent vaccine
BRPI1007721B1 (en) vaccine composition for use in inducing an immune response against a rotavirus in an individual, a rotavirus strain isolated from cdc-9 and a rotavirus strain isolated from cdc-66
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
WO2013052859A3 (en) Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
MX2010003713A (en) Cytomegalovirus vaccines and methods of production.
WO2011090708A3 (en) Recombinant ndv antigen and uses thereof
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2009115917A3 (en) Improvements in preparation of influenza virus vaccine antigens
CO6670515A2 (en) Parapoxvirus Vectors
CO6541529A2 (en) METHOD, PLASMIDEO AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST VIRUSES OF DENGUE BASED ON DNA VACCINES AND CHEMICAL VIRUSES
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
WO2011106705A3 (en) Dna-protein vaccination protocols
EA201200538A1 (en) ARABINOGALAKTAN TO IMPROVE ACQUIRED IMMUNE RESPONSE
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10778804

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10778804

Country of ref document: EP

Kind code of ref document: A2